Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Stroli – the shopping trolley reimagined for modern needs. The shopping trolley, often associated with a particular image, is an untapped category ready for innovation. The market is flooded with generic, budget-friendly options that lack charm, with the exception of Rolser, which is pricier and claims the green niche. Stroli steps in as the go-to brand, offering a unique approach, positioning, voice, and eco-friendly credentials. Say goodbye to sore hands and plastic bags – Stroli makes shopping a pleasure with its high-quality, stylish trolley bags designed to enhance your convenience and style
days to go:
Extended
investment:
Withheld
Yolk, also known as In One Basket Limited, is a pioneering company revolutionizing the food and coffee experience for people on the move. They provide high-quality sandwiches, salads, and improved breakfast options without the premium cost, boasting five successful locations in London and three upcoming openings in the second half of 2023
days to go:
TBC
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
East London Liquor Company export from east London to 20 countries worldwide. They have plans to launch in Ibiza, Toronto, Los angles, New York and Shanghai. They also own their own restaurant. Since 2014 they have grown there team from 4 to 30 people. London dry gin has won many award and the East London Liquor Company produces over 12,000 bottles of gin a month.
days to go:
Expired
investment:
£1,326,450
Software as a Service (SaaS) business for Recruitment generating recurring revenues on a scalable cloud platform. Used by HR, Recruiting Teams and HR Managers. Proven that we can sell to our target market we seek growth capital to build out our chosen go to market strategy.
days to go:
Expired
investment:
£280,000
Caldera is a heat battery company that seeks to institutionalise zero-carbon energy solutions for the masses. Its patented breakthrough, Warmstone heat battery, can store 100kWh of heat for a standard home for 24 hours. Caldera asserts that it takes renewable energy using a flexible green tariff with prices as low as 5p/kWh and stores it as heat, providing carbon-free hot water and heating via Warmstone. The company has raised over £1.5 million through grants and investment to date, installed its first pilot Warmstone product in a family home, established a manufacturing and R&D base, and acquired the support of an energy think tank, Energy Systems Catapult. It aspires to become a contender in the estimated £3.5 billion renewable energy storage market in the European Union (EU). The company is working with König Metall to build and sell Warmstone units via approved UK installers. Caldera will use the investment to install a small number of pilot units in trial homes in 2021 before a full commercial rollout in 2022.
days to go:
Expired
investment:
£1,572,524
B-North is a UK-based business lending company. It has combined cloud-native technology with face-to-face relationship banking. The company asserts that SMEs account for over 60% of private-sector employment in the UK, have driven job growth over the past ten years, and are central to driving economic recovery. It intends to disrupt the £150 billion UK Small and Medium Enterprise (SME) lending market. B-North has raised a seed capital of over £6.8 million including a six-figure investment from the Greater Manchester Combined Authority to establish its core team, as well as, build lending and deposit-taking platforms. The company is now seeking further investment through a bridge round to extend the cash runway from the end of Q4 2020 into Q1-Q2 2021 to achieve the necessary regulatory capital to become a bank and commence lending.
days to go:
Expired
investment:
£2,149,256
